Structure of SARS-CoV-2 3CL protease in complex with inhibitor 17c

(1R,2S)-2-((S)-2-((((2-fluorobenzyl)oxy)carbonyl)amino)-4-methylpentanamido)-1-hydroxy-3-((R)-2-oxo-3,4-dihydro-2H-pyrrol-3-yl)propane-1-sulfonic acid

(1S,2S)-2-((S)-2-((((2-fluorobenzyl)oxy)carbonyl)amino)-4-methylpentanamido)-1-hydroxy-3-((R)-2-oxo-3,4-dihydro-2H-pyrrol-3-yl)propane-1-sulfonic acid

Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies.

3CL-PRO, 3CLp, Main protease, Mpro, Non-structural protein 5, nsp5, SARS coronavirus main proteinase

Severe acute respiratory syndrome coronavirus 2

30% w/v PEG2000 MME, 100 mM potassium thiocyanate

National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)

COVID-19, PROTEASE, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 3CL protease Inhhibitors, HYDROLASE-INHIBITOR complex